Journal
BIOLOGICALS
Volume 39, Issue 5, Pages 293-296Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biologicals.2011.06.024
Keywords
Biosimilars; Similar biotherapeutic products; Somatropin; Filgrastim; Erythropoietin; Clinical development
Ask authors/readers for more resources
Similar biotherapeutic products (SBPs) or biosimilars are biologics developed by pharmaceutical manufacturers to match originator biologics that have been on the market for a long time and lost their exclusivity (patent and market protection). The recently issued WHO guidelines on evaluation of SBPs provide clear guidance for manufacturers and regulators on how to develop and gain approval for these products. The present contribution illustrates the rationale for and general principles of the clinical programs used in the development of SBPs, taking the example of the three biosimilar products developed and marketed in Europe by Sandoz, namely growth hormone (Omnitrope (R), the first ever EU biosimilar approval), erythropoietin alpha (Binocrit (R)), and filgrastim (Zarzio (R)). (C) World Health Organization 2011. All rights reserved. The World Health Organization has granted the Publisher permission for the reproduction of this article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available